//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org. Follow @ai.nejm.org for medical AI content.
NEJM.org









Loading...
In this study involving 12 patients with X-linked retinoschisis who received subretinal gene therapy, no adverse events of grade 3 or higher were reported, and changes in retinal structure were consistent with a therapeutic effect. Full study results: https://nej.md/4ofdSGk
For interviewing residency applicants, would you recommend continuing virtual-only residency interviews or support a return to in-person residency interviews? Vote on the best option: https://nej.md/4x7Tefc
Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. Full study results: https://nej.md/4dXZ3od
Paul Bastard, MD, PhD, and Jean-Laurent Casanova, MD, PhD, describe the scientific foundations of a study implicating autoantibodies against interleukin-10 in persons with inflammatory bowel disease. Read the editorial: https://nej.md/4e1EZ4s
In a new blog post, Dr. Michelle Kittleson (@mkittlesonmd.bsky.social) recalls a moment when a heart transplant patient taught her symptoms aren’t always medical. Read “Life Is a Series of Dogs”: https://voices.nejm.org/doi/full/10.1056/VOICESpost2600017
In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days. Full TRACTION trial results: https://nej.md/4e8QKF4
In our latest video in partnership with @glaucomflecken.bsky.social, Gynecology meets Urology to settle their "hormone beef" with a trial assessing the safety and efficacy of transdermal estradiol patches in patients with prostate cancer. Read the full study for free: nej.md/DrG42
Among critically ill adults with acute respiratory failure, neither carbocisteine nor hypertonic saline reduced the duration of mechanical ventilation, and each strategy was associated with harm. Full phase 3 MARCH trial results: https://nej.md/3PUyHdA #CCR26 | @criticalcarereviews.com
In a patient with recurrent ameloblastoma, zolucatetide (formerly FOG-001) produced an ongoing partial response at 40 weeks, with resolution of solid tumor and cerebral edema. Elevated liver-enzyme levels were noted. Full study results: https://nej.md/4e5IgON
Among patients who were unresponsive after cardiac arrest, conservative oxygen therapy did not increase 180-day survival with favorable function as compared with liberal oxygen therapy. Full LOGICAL trial results: https://nej.md/4x7TavY #CCR26 | @criticalcarereviews.com
6h
9h
7h
6h
12h
15h
Video
1d
17h
1d
19h
Video
NEJM.org
NEJM.org
NEJM.org
NEJM.org
NEJM.org
NEJM.org
NEJM.org
NEJM.org
NEJM.org
NEJM.org